BRCA1 and neoplasm: Patient tumors harboring DDR mutations, including 1100delC CHEK2 mutants and/or BRCA1/2 deleterious variants, showed higher percentages of tumor shrinkage (ORR = 86%) and longer overall survival (PFS = 30 months).